Loading stock data…
REGENXBIO Inc. (RGNX)
$11.83+1.35 (+12.88%)
After Hours$11.84+0.01 (+0.08%)· Last close Jun 29
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
REGENXBIO Inc. in the Healthcare sector is trading at $11.83 with a market capitalization of $346M. Wall Street consensus targets $24.36 (11 analysts), implying a +105.9% move over the next 12 months. The stock is currently 27% below its 52-week high of $16.19, remaining 14.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +105.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.39M↓ | $30.34M↑ | $29.73M↑ | $21.36M↓ | $89.01M |
| Gross Profit | -$4.68M↓ | $24.41M↑ | $24.01M↑ | $16.15M↓ | $85.58M |
| Operating Income | -$83.36M↓ | -$57.64M↓ | -$52.41M↑ | -$63.28M↓ | $12.13M |
| Net Income | -$90.05M↓ | -$67.15M↓ | -$61.94M↑ | -$70.87M↓ | $6.08M |
Peer Comparison
JNJUNHPFE
Fundamentals
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$345.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1375.64%
Volume
Today's trading volume
2.41M
Recent News
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.
FDA changes rare disease tune again as it clears path for Regenxbio’s gene therapy
With a regulatory route now in place, Regenxbio expects to meet with the FDA again in July, with a BLA resubmission to follow in Q3 2026.
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.9% and
AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers
On this episode of Stock Movers with Nathan Hager: - Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report. - Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn't need to conduct additional studies of the drug. - SpaceX (SPCX) is lower this morning, continuing its slide after its record IPO.
RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbio’s Hunter Syndrome Therapy
The U.S. Food and Drug Administration has agreed to reconsider Regenxbio’s application for its experimental gene therapy Navsunli.